AbbVie Q1 2026 Earnings: $15B Revenue Beats, Adjusted EPS $2.65 Smashes Estimates, Full-Year Guidance Raised
wealthvista.top Editorial · May 25, 2026 · 12 min read
AbbVie Inc. (ABBV) — Q1 2026 Earnings Analysis
Executive Summary
AbbVie Inc. (NYSE: ABBV) delivered a Q1 2026 performance that exceeded consensus expectations on both the top and bottom lines, underpinned by continued strong momentum from its immunology growth platform and a broadly diversified product portfolio. The company reported net revenues of $15,002 million, up 12.4% year-over-year (including a 1.0% unfavorable foreign exchange impact), compared to $13,343 million in Q1 2025. On a non-GAAP adjusted basis, diluted EPS reached $2.65, surpassing the $2.46 reported in the prior-year quarter — a +7.7% increase.
GAAP diluted EPS came in at $0.39, sharply below the $0.72 reported in Q1 2025, reflecting substantial one-time charges: $2,387 million in fair value changes in contingent consideration related to the ImmunoGen acquisition, and $744 million in acquired IPR&D and milestones. Excluding these specified items, the adjusted business model proved robust.
Buoyed by first-quarter outperformance, AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16, implying meaningful upside relative to Wall Street expectations.
1. Company Overview
| Attribute | Details |
|---|---|
| Company | AbbVie Inc. |
| Ticker | ABBV (NYSE) |
| Headquarters | North Chicago, Illinois, USA |
| Founded | 2013 (spun off from Abbott Laboratories) |
| CEO | Richard A. Gonzalez |
| Fiscal Year End | December 31 |
| Market Capitalization | ~$300 billion |
| Primary Segments | Immunology, Neuroscience, Oncology, Aesthetics |
| Key Products | Skyrizi, Rinvoq, Humira, Vraylar, Botox, Imbruvica, Venclexta |
AbbVie is one of the world’s largest research-based biopharmaceutical companies, with a diversified portfolio spanning immunology (its largest franchise), neuroscience, oncology, and aesthetics (following the 2020 Allergan acquisition). The company generates revenues globally across the United States and international markets.
2. Q1 2026 Financial Performance
2.1 Consolidated Earnings Summary
| Metric | Q1 2026 | Q1 2025 | Change (YoY) |
|---|---|---|---|
| Net Revenues | $15,002M | $13,343M | +12.4% |
| U.S. Revenues | $10,969M | $9,977M | +9.9% |
| International Revenues | $4,033M | $3,366M | +19.9% |
| Cost of Products Sold | $4,218M | $4,002M | +5.4% |
| SG&A | $3,578M | $3,293M | +8.6% |
| R&D | $2,472M | $2,067M | +19.6% |
| Acquired IPR&D & Milestones | $744M | $248M | +200% |
| Operating Earnings | $3,990M | $3,733M | +6.9% |
| Interest Expense, Net | $645M | $627M | +2.9% |
| Other Expense, Net | $2,306M | $1,445M | +59.6% |
| Earnings Before Tax | $1,039M | $1,661M | -37.4% |
| Income Tax Expense | $342M | $372M | -8.1% |
| Net Earnings (GAAP) | $697M | $1,289M | -45.9% |
| Net Earnings Attributable to AbbVie | $695M | $1,286M | -46.0% |
| Diluted EPS (GAAP) | $0.39 | $0.72 | -45.8% |
| Adjusted Diluted EPS (Non-GAAP) | $2.65 | $2.46 | +7.7% |
| Weighted Avg. Diluted Shares | 1,774M | 1,772M | +0.1% |
Revenue Beat/Miss: AbbVie reported Q1 net revenues of $15,002M, which beat the Wall Street consensus estimate of approximately $14,600M by roughly $400M (+2.8%).
EPS Beat/Miss (Adjusted): Adjusted diluted EPS of $2.65 beat the analyst consensus of approximately $2.50 by $0.15 per share (+6.0%).
GAAP EPS Beat/Miss: GAAP diluted EPS of $0.39 missed consensus estimates of approximately $0.70, but this is a non-recurring, acquisition-related distortion.
2.2 Segment Revenue Performance
Immunology — The Growth Engine
| Product | Q1 2026 Revenue | Q1 2025 Revenue | YoY Growth (Operational) |
|---|---|---|---|
| Skyrizi (risankizumab) | $4,483M | $3,428M | +30.9% (+28.0% operational) |
| Rinvoq (upadacitinib) | $2,119M | $1,718M | +23.3% (+32.6% operational) |
| Humira (adalimumab) | $688M | $1,120M | -38.6% (-40.3% operational) |
| Total Immunology | $7,290M | $5,246M | +38.9% / +16.4% total (+17.3% operational) |
Immunology is AbbVie’s crown jewel and the primary driver of its growth narrative:
- Skyrizi continues to be a blockbuster growth driver, posting nearly +31% revenue growth on the back of expanded indications in psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
- Rinvoq shows robust growth of +23% (or +32.6% operational, when excluding foreign exchange), benefiting from market share gains in rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis.
- Humira, once the world’s best-selling drug, is facing significant biosimilar erosion (-38.6% reported, -40.3% operational), consistent with management’s expectations as multiple biosimilar competitors have entered the U.S. market. This is a known and anticipated headwind.
Net takeaway: The Skyrizi + Rinvoq growth engine more than offsets Humira’s decline, demonstrating successful product lifecycle management.
Neuroscience — Emerging Growth Platform
| Product | Q1 2026 Revenue | YoY Growth (Total) | Notes |
|---|---|---|---|
| Vraylar (cariprazine) | $905M | +18.4% | Strong in bipolar disorder & major depressive disorder (MDD) |
| Botox Therapeutic | $1,009M | +16.5% | Chronic migraine and other neurological indications |
| Ubrelvy (ubrogepant) | $339M | +41.4% | Oral CGRP antagonist for acute migraine |
| Qulipta (atogepant) | $296M | +53.6% | Oral CGRP antagonist for migraine prevention |
| Vyalev (levodopa) | $201M | >+100% | Parkinson disease, recently launched |
| Total Neuroscience | $2,875M | +26.0% (+24.3% operational) | Growth accelerating |
The neuroscience franchise is rapidly becoming AbbVie’s second pillar, with multiple drugs firing on all cylinders. Vraylar, Botox Therapeutic, and the CGRP franchise (Ubrelvy + Qulipta) are all delivering mid-teens to high-forties growth. The recent FDA approval of Vyalev (a continuous subcutaneous levodopa infusion for Parkinson’s disease) adds a novel mechanism with significant commercial potential.
Oncology — Mixed Performance
| Product | Q1 2026 Revenue | YoY Growth | Notes |
|---|---|---|---|
| Venclexta (venetoclax) | $770M | +15.7% | Solid growth in CLL and AML |
| Imbruvica (ibrutinib) | $556M | -24.7% (+7.2% int’l profit share) | US decline due to competition; int’l stable |
| Elahere (mirvetuximab) | $198M | +10.7% | FRα-positive ovarian cancer |
| Epkinly (epcoritamab) | $83M | +62.0% (+81.8% int’l) | Bispecific antibody for DLBCL |
| Total Oncology | $1,631M | -0.2% (-3.0% operational) | Roughly flat overall |
Oncology presents a mixed picture. Venclexta continues to grow steadily, while Imbruvica faces competitive pressure in its chronic lymphocytic leukemia (CLL) indication, particularly from礼来’s Jaypirca (pirtobrutinib). However, the international profit-sharing arrangement moderates the financial impact. Elahere and Epkinly (both from the ImmunoGen acquisition) are early but growing fast, suggesting the acquisition is beginning to contribute.
Aesthetics — Steady but Modest
| Product | Q1 2026 Revenue | YoY Growth |
|---|---|---|
| Botox Cosmetic | $668M | +20.2% |
| Juvederm Collection | $232M | +0.4% |
| Other Aesthetics | $286M | -9.4% |
| Total Aesthetics | $1,186M | +7.6% (+5.1% operational) |
The aesthetics business delivered steady mid-single-digit growth, with Botox Cosmetic performing particularly well as the aesthetic injectables market remains robust.
Other Key Products
| Product | Q1 2026 Revenue | YoY Growth |
|---|---|---|
| Mavyret (glecaprevir/pibrentasvir) | $351M | +8.6% |
| Creon (pancrelipase) | $361M | +1.8% |
| Linzess (linaclotide) | $283M | +90.9% |
| Total | $995M | +23.0% |
Linzess in particular showed exceptional growth (+90.9%), driven by increased adoption for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
3. Key Strategic Developments
3.1 Post-Brexit / Post-Humira Transition
AbbVie’s management has successfully executed the post-Humira loss-of-exclusivity transition plan. Rather than experiencing the revenue cliff that often devastates pharma giants after patent expirations, AbbVie has managed the decline through:
- Rapid Skyrizi and Rinvoq uptake: Both drugs are growing at 20–30%+ rates and are on track to collectively exceed peak Humira revenues within the next 2–3 years.
- International expansion: Both drugs are still in early-to-mid stages of international launches, providing multi-year growth runway.
- Pipeline progression: Label expansions for Skyrizi and Rinvoq across additional autoimmune indications continue to widen the addressable market.
3.2 ImmunoGen Acquisition (Completed 2024)
The acquisition of ImmunoGen (now rebranded as part of AbbVie’s oncology unit) brought:
- Elahere — a first-in-class FRα-directed antibody-drug conjugate (ADC) for platinum-resistant ovarian cancer, now growing rapidly post-launch.
- Epkinly — a bispecific antibody for diffuse large B-cell lymphoma (DLBCL), gaining market share.
- Cadzyn (ALLO-501/501A) — allogeneic CAR-T cell therapy candidates in the pipeline.
The significant fair value change in contingent consideration ($2,325 million pre-tax) recognized in Q1 2026 reflects accounting adjustments tied to this acquisition’s earnout structure, but does not reflect operational underperformance.
3.3 Regulatory & Pipeline Updates
- Skyrizi (risankizumab) continues to expand globally across inflammatory bowel disease (IBD) and pediatric populations.
- Rinvoq (upadacitinib) received additional approvals for systemic juvenile idiopathic arthritis (sJIA) and strengthened its position in atopic dermatitis.
- Vyalev (levodopa infusion) represents a novel Parkinson’s treatment approved in 2024, with early commercial traction.
4. GAAP vs. Non-GAAP Reconciliation
AbbVie provides non-GAAP adjusted financial measures that exclude specified items, which the company’s management believes provide more useful insight into underlying business performance:
| Item | Q1 2026 Impact (Pre-tax) | EPS Impact (Diluted) |
|---|---|---|
| Intangible asset amortization | $1,748M | $0.85 |
| Change in fair value of contingent consideration | $2,387M | $1.31 |
| Other specified items | $395M | ~$0.14 |
| Total specified items | ~$4,530M | ~$2.30 |
This explains the large gap between GAAP diluted EPS ($0.39) and non-GAAP adjusted diluted EPS ($2.65). The largest single item — the $2,387 million change in contingent consideration — is a non-cash, accounting-driven charge related to the ImmunoGen acquisition, and does not reflect underlying business performance or cash generation.
5. Financial Position
5.1 Balance Sheet Strength
AbbVie maintains a strong investment-grade balance sheet with substantial cash flow generation:
- Operating Cash Flow (Q1 TTM): AbbVie generates multi-billion-dollar annual operating cash flows, comfortably covering debt service and capital allocation priorities.
- Debt: AbbVie carries significant long-term debt (approximately $58–60 billion) from the Allergan and ImmunoGen acquisitions, but the company maintains strong interest coverage ratios given its cash flow profile.
- Capital Returns: AbbVie has a long-standing commitment to returning capital to shareholders via dividends. The company has increased its dividend for 12+ consecutive years, and ABBV now yields approximately 3.6% at current prices.
5.2 R&D Investment
R&D spend reached $2,472 million in Q1 2026 (+19.6% YoY), reflecting AbbVie’s commitment to pipeline investment. Key areas of focus include:
- Next-generation immunology assets (Skyrizi and Rinvoq line extensions)
- Oncology expansion (ADCs, bispecifics, CAR-T)
- Neuroscience new chemical entities and lifecycle management
6. 2026 Full-Year Guidance
AbbVie entered 2026 with initial adjusted diluted EPS guidance of $13.96–$14.16. Following Q1 outperformance, the company raised its full-year guidance:
| Metric | Original FY2026 Guidance | Revised FY2026 Guidance |
|---|---|---|
| Adjusted Diluted EPS | $13.96–$14.16 | $14.08–$14.28 |
Key guidance assumptions:
- Full-year net revenue growth expected to be driven by continued Skyrizi and Rinvoq momentum
- Humira revenue expected to decline significantly (consistent with ongoing biosimilar erosion)
- R&D investment expected to remain elevated
- Full-year adjusted tax rate expected to be approximately 19–21%
7. Valuation
At approximately $215.70 per share and a market capitalization of ~$300 billion, AbbVie trades at roughly:
| Metric | Approximate Value |
|---|---|
| P/E (Non-GAAP Adjusted, TTM) | ~20x |
| P/E (GAAP, TTM) | ~N/M (distorted by one-time charges) |
| EV/EBITDA | ~16–18x |
| Dividend Yield | ~3.6% |
| Price/Sales | ~5x |
At current levels, ABBV appears reasonably valued relative to large-cap pharma peers, with the premium justified by the company’s strong growth profile (Skyrizi/Rinvoq), diversified pipeline, and attractive dividend yield.
8. Risks and Considerations
| Risk | Description |
|---|---|
| Humira Biosimilar Erosion | Continued and accelerating decline in Humira revenues as more biosimilar competitors enter the U.S. market. Management expects this, but the pace of decline bears monitoring. |
| Skyrizi/Rinvoq Competition | Both drugs face competition from other IL-23 inhibitors (Johnson & Johnson’s Tremfya) and JAK inhibitors (Eli Lilly’s Olumiant, Pfizer’s Xeljanz). Sustained growth requires successful defense of market share. |
| JAK Inhibitor Class Safety | Rinvoq carries class warnings for JAK inhibitor safety concerns (boxed warning for serious infections, malignancy, and cardiovascular events). Regulatory scrutiny and physician prescribing behavior remain watch items. |
| Acquisition Integration Risk | The ImmunoGen acquisition introduces integration risk and the contingent consideration fair value changes create earnings volatility. |
| FX Risk | With ~27% of revenues from international markets, currency fluctuations can impact reported revenue growth. |
| Pipeline Failures | Clinical-stage pipeline assets could fail or face regulatory setbacks, affecting long-term growth prospects. |
| Debt Load | ~$58–60 billion in long-term debt requires continued strong cash flow generation to service. |
9. Investment Conclusion
Verdict: Positive — Exceeding Expectations with a Sustainable Growth Narrative
AbbVie’s Q1 2026 results reinforce the thesis that the company has successfully navigated its most significant patent cliff event (Humira exclusivity loss) and is now delivering sustainable double-digit revenue growth driven by best-in-class immunology assets.
Bull Case:
- Skyrizi and Rinvoq are firing on all cylinders with clear runway to become the two largest immunology drugs globally by peak sales
- The neuroscience franchise is emerging as a powerful third pillar
- Management’s raise of full-year 2026 guidance signals confidence in continued outperformance
- Attractive dividend yield (~3.6%) provides fundamental support
- Pipeline investments in oncology (Elahere, Epkinly) and neuroscience (Vyalev) provide multi-year growth optionality
Bear Case / Caution:
- GAAP earnings are heavily distorted by non-cash, acquisition-related charges — investors should focus on non-GAAP metrics
- Humira decline is steep and could accelerate beyond expectations
- The JAK inhibitor class carries ongoing regulatory risk for Rinvoq
- Valuation is not cheap at ~20x non-GAAP P/E, leaving limited upside to analyst targets
Overall: AbbVie is well-positioned as a quality large-cap pharmaceutical holding with a combination of growth (immunology new products), diversification (neuroscience), income (dividend), and innovation (pipeline). The Q1 beat and guidance raise make ABBV a compelling name for investors seeking pharma sector exposure with a清晰的 post-Humira transition success story.
10. Data Sources
- SEC EDGAR — AbbVie 10-Q (Q1 2026, filed May 8, 2026)
- SEC EDGAR — AbbVie 8-K (Q1 Earnings Press Release, April 29, 2026)
- Yahoo Finance — ABBV Real-Time Quote
- AbbVie Investor Relations: investors.abbvie.com
Report generated by Alpha Arvion Analytics. For informational purposes only. Not investment advice. Past performance does not guarantee future results.